Zydus Lifesciences
ZYDUSLIFE · NSE
Public Market Listing
Live quotes, historical charts, and market capitalization for Zydus Lifesciences are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | VEGF-AMonoclonal antibody | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
| Phase 3 | CTLA-4Monoclonal antibody | Non-Small Cell Lung CancerColorectal Cancer | |
Desidustat(Oxemia) | Phase 3 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
Saroglitazar(Lipaglyn) | Phase 3 | PPAR-alpha/PPAR-gammaSmall molecule | Type 2 DiabetesCardiovascular Disease / DyslipidemiaCholestatic Liver Disease Hypertriglyceridemia, Primary Biliary Cholangitis |
| Phase 2 | PD-1Monoclonal antibody | Non-Small Cell Lung CancerCervical Cancer |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (1)
July 2028 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q4 | $829M | $76M | — | — | report ↗ |
Zydus Lifesciences reported revenue of $829.02M, down 69.8% YoY and R&D spend of $76.29M, down 65.2% YoY for Q4 2026.
Figures only: this period's report disclosed no narrative text
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $771M | — | — | — | report ↗ |
| 2026-Q2 | $702M | — | — | — | report ↗ |
| 2026-Q1 | $769M | — | — | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $3.1B | $256M | — | — | report ↗ |